Agios Pharmaceuticals’ mitapivat shows significant promise in Phase 3 ENERGIZE study

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a pioneer in cellular metabolism and pyruvate kinase (PK) activation therapies, unveiled detailed results from the Phase 3 ENERGIZE study ... Read More